SCLX
Scilex Holding Company
There isn't enough reported data to score SCLX yet.
SCLX Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Unavailable | |
| Unavailable |
SCLX's revenue and profitability are currently under pressure. There isn't enough data to rate its cash flow and balance sheet.
SCLX PE Valuation
SCLX has no meaningful PE right now: it lost money over the past year. If it returns to profit as analysts expect, today's price would be 5.5x next year's earnings.
SCLX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Returning to profit | |
| Strong growth | |
| Strongly weakening | |
| Limited | |
| High |
Analysts expect SCLX to return to profit, with revenue growing.
SCLX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.28 | — |
| Q3 2025 | -$31.88 | -$3.18 |
SCLX lost $31.88 per share over the past year, a bigger loss than the year before.
SCLX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $7.6M | -23% |
| Q1 2026 | $8.6M | +72% |
| Q4 2025 | $4.8M | -68% |
| Q3 2025 | $10.6M | -27% |
| Q2 2025 | $9.9M | -40% |
| Q1 2025 | $5M | -54% |
| Q4 2024 | $14.9M | +11% |
| Q3 2024 | $14.4M | +43% |
SCLX's revenue has slid since its 2024 peak: $8M last quarter, down 23% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -385% | -178 points |
| Q1 2026 | -373% | +184 points |
| Q4 2025 | -2318% | -2127 points |
| Q3 2025 | -1766% | -1628 points |
| Q2 2025 | -207% | -112 points |
| Q1 2025 | -558% | -379 points |
| Q4 2024 | -190% | -54 points |
| Q3 2024 | -138% | +246 points |
SCLX's operating margin was −385% last quarter, down 178 points from the same quarter a year ago.
SCLX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q1 2026 | -$1.1M | -118% |
| Q3 2025 | $8.2M | +61% |
| Q1 2025 | $6M | -36% |
| Q4 2024 | $2.5M | +$7.9M |
| Q3 2024 | $5.1M | -13% |
| Q1 2024 | $9.4M | +$17.1M |
| Q3 2023 | $5.9M | +$6.2M |
| Q1 2023 | -$7.7M | -$6.9M |
SCLX usually generates cash, though not every quarter: the latest was −$1M, but it generated $20M over the past year.
SCLX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -23% | -115K shares |
| 1 year | -24% | -116K shares |
SCLX has 376,468 diluted shares, down 24% from a year ago.
SCLX Net Leverage
SCLX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
SCLX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 29.4 | Oversold |
| Stochastic | 0.8 | Oversold |
SCLX's weekly RSI is 29 (oversold) and its Stochastic is 1 (oversold).
SCLX PE vs Healthcare Sector
| Metric | SCLX | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
SCLX has no meaningful PE right now: it lost money over the past year.
SCLX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.77 | 44% below |
| 20 week MA | $5.09 | 69% below |
| 50 week MA | $7.45 | 79% below |
| 100 week MA | $10.2 | 85% below |
| 200 week MA | $62.2 | 97% below |
SCLX is in a downtrend: it's below all five of its weekly moving averages, and 97% below its 200-week average.
SCLX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $344.8 | $351.4 | +1.9% |
| 2022 | $351.4 | $117.3 | -67% |
| 2023 | $117.3 | $71.4 | -39% |
| 2024 | $71.4 | $13.7 | -81% |
| 2025 | $13.7 | $14.1 | +3.3% |
| 2026 YTD | $14.1 | $1.56 | -89% |
SCLX has finished lower in three of the last five years. It's down 89% so far in 2026.